

Jan Konvalinka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7513935/publications.pdf>

Version: 2024-02-01

143
papers

4,766
citations

87888

38
h-index

123424

61
g-index

147
all docs

147
docs citations

147
times ranked

4705
citing authors

#	ARTICLE	IF	CITATIONS
1	From nonpeptide toward noncarbon protease inhibitors: Metallacarboranes as specific and potent inhibitors of HIV protease. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 15394-15399.	7.1	279
2	Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO Journal, 2006, 25, 1375-1384.	7.8	241
3	A Novel Substrate-Based HIV-1 Protease Inhibitor Drug Resistance Mechanism. PLoS Medicine, 2007, 4, e36.	8.4	146
4	Design of HIV Protease Inhibitors Based on Inorganic Polyhedral Metallacarboranes. Journal of Medicinal Chemistry, 2009, 52, 7132-7141.	6.4	132
5	Expression of glutamate carboxypeptidase II in human brain. Neuroscience, 2007, 144, 1361-1372.	2.3	116
6	A Reliable Docking/Scoring Scheme Based on the Semiempirical Quantum Mechanical PM6-DH2 Method Accurately Covering Dispersion and H-Bonding: HIV-1 Protease with 22 Ligands. Journal of Physical Chemistry B, 2010, 114, 12666-12678.	2.6	116
7	Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. Journal of Neurochemistry, 2002, 80, 477-487.	3.9	113
8	Retroviral proteases and their roles in virion maturation. Virology, 2015, 479-480, 403-417.	2.4	109
9	Different requirements for productive interaction between the active site of HIV-1 proteinase and substrates containing -hydrophobic-hydrophobic- or -aromatic-Pro- cleavage sites. Biochemistry, 1992, 31, 5193-5200.	2.5	107
10	Dual Substrate and Reaction Specificity in Mouse Serine Racemase: Identification of High-Affinity Dicarboxylate Substrate and Inhibitors and Analysis of the β^2 -Eliminase Activity. Biochemistry, 2005, 44, 13091-13100.	2.5	106
11	Current and Novel Inhibitors of HIV Protease. Viruses, 2009, 1, 1209-1239.	3.3	102
12	MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition. PLoS Biology, 2019, 17, e3000354.	5.6	94
13	Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein Science, 2004, 13, 1627-1635.	7.6	93
14	Inorganic Polyhedral Metallacarborane Inhibitors of HIV Protease: A New Approach to Overcoming Antiviral Resistance. Journal of Medicinal Chemistry, 2008, 51, 4839-4843.	6.4	90
15	Structural Basis of Interactions between Human Glutamate Carboxypeptidase II and Its Substrate Analogs. Journal of Molecular Biology, 2008, 376, 1438-1450.	4.2	79
16	Mouse brain serine racemase catalyzes specific elimination of L-serine to pyruvate. FEBS Letters, 2003, 535, 44-48.	2.8	78
17	Hydrolysis of synthetic chromogenic substrates by HIV-1 and HIV-2 proteinases. Biochemical and Biophysical Research Communications, 1990, 171, 439-444.	2.1	76
18	Molecular Analysis of the HIV-1 Resistance Development: Enzymatic Activities, Crystal Structures, and Thermodynamics of Nelfinavir-resistant HIV Protease Mutants. Journal of Molecular Biology, 2007, 374, 1005-1016.	4.2	74

#	ARTICLE	IF	CITATIONS
19	Structural Insight into the Pharmacophore Pocket of Human Glutamate Carboxypeptidase II. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 3267-3273.	6.4	71
20	Random protein sequences can form defined secondary structures and are well-tolerated in vivo. <i>Scientific Reports</i> , 2017, 7, 15449.	3.3	68
21	A possible regulation of negative factor (Nef) activity of human immunodeficiency virus type 1 by the viral protease. <i>FEBS Journal</i> , 1994, 223, 589-593.	0.2	58
22	Reaction Mechanism of Glutamate Carboxypeptidase II Revealed by Mutagenesis, X-ray Crystallography, and Computational Methods. <i>Biochemistry</i> , 2009, 48, 4126-4138.	2.5	56
23	Urea and Guanidinium Induced Denaturation of a Trp-Cage Miniprotein. <i>Journal of Physical Chemistry B</i> , 2011, 115, 8910-8924.	2.6	56
24	Structure-Aided Design of Novel Inhibitors of HIV Protease Based on a Benzodiazepine Scaffold. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10130-10135.	6.4	53
25	Biochemical characterization of human glutamate carboxypeptidase III. <i>Journal of Neurochemistry</i> , 2006, 101, 682-696.	3.9	51
26	Sub-site preferences of the aspartic proteinase from the human immunodeficiency virus, HIV-1. <i>FEBS Letters</i> , 1990, 268, 35-38.	2.8	50
27	Expression and distribution of high affinity glutamate transporters GLT1, GLAST, EAAC1 and of GCP II in the rat peripheral nervous system. <i>Journal of Anatomy</i> , 2008, 213, 539-546.	1.5	50
28	Malonate-based inhibitors of mammalian serine racemase: Kinetic characterization and structure-based computational study. <i>European Journal of Medicinal Chemistry</i> , 2015, 89, 189-197.	5.5	49
29	A high-resolution structure of ligand-free human glutamate carboxypeptidase II. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2007, 63, 150-153.	0.7	48
30	Thermodynamic and structural analysis of HIV protease resistance to darunavir: Analysis of heavily mutated patient-derived HIV-1 proteases. <i>FEBS Journal</i> , 2014, 281, 1834-1847.	4.7	48
31	Unusual Binding Mode of an HIV-1 Protease Inhibitor Explains its Potency against Multi-drug-resistant Virus Strains. <i>Journal of Molecular Biology</i> , 2002, 324, 739-754.	4.2	46
32	Inhibition of Human Serine Racemase, an Emerging Target for Medicinal Chemistry. <i>Current Drug Targets</i> , 2011, 12, 1037-1055.	2.1	46
33	Human DNA-Damage-Inducible 2 Protein Is Structurally and Functionally Distinct from Its Yeast Ortholog. <i>Scientific Reports</i> , 2016, 6, 30443.	3.3	46
34	Structural studies of the yeast DNA damage-inducible protein Ddi1 reveal domain architecture of this eukaryotic protein family. <i>Scientific Reports</i> , 2016, 6, 33671.	3.3	44
35	Molecular Characterization of Clinical Isolates of Human Immunodeficiency Virus Resistant to the Protease Inhibitor Darunavir. <i>Journal of Virology</i> , 2009, 83, 8810-8818.	3.4	43
36	Tissue expression and enzymologic characterization of human prostate specific membrane antigen and its rat and pig orthologs. <i>Prostate</i> , 2008, 68, 171-182.	2.3	42

#	ARTICLE	IF	CITATIONS
37	Proteolytic Processing of Particle-Associated Retroviral Polyproteins by Homologous and Heterologous Viral Proteinases. <i>FEBS Journal</i> , 1995, 228, 191-198.	0.2	42
38	Cell-Based Fluorescence Assay for Human Immunodeficiency Virus Type 1 Protease Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 2616-2622.	3.2	41
39	Mutations in HIV-1 <i>gag</i> and <i>pol</i> Compensate for the Loss of Viral Fitness Caused by a Highly Mutated Protease. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4320-4330.	3.2	40
40	Systematic mutational analysis of the active-site threonine of HIV-1 protease: Rethinking the "fireman's grip" hypothesis. <i>Protein Science</i> , 2000, 9, 1631-1641.	7.6	39
41	Ninety-Nine Is Not Enough: Molecular Characterization of Inhibitor-Resistant Human Immunodeficiency Virus Type 1 Protease Mutants with Insertions in the Flap Region. <i>Journal of Virology</i> , 2008, 82, 5869-5878.	3.4	39
42	Specific Inhibitors of HIV Capsid Assembly Binding to the C-Terminal Domain of the Capsid Protein: Evaluation of 2-Arylquinazolines as Potential Antiviral Compounds. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 545-558.	6.4	39
43	Molecular recognition of fibroblast activation protein for diagnostic and therapeutic applications. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2020, 1868, 140409.	2.3	39
44	Recombinant human serine racemase: Enzymologic characterization and comparison with its mouse ortholog. <i>Protein Expression and Purification</i> , 2009, 63, 62-67.	1.3	38
45	Rational design of urea-based glutamate carboxypeptidase II (GCPII) inhibitors as versatile tools for specific drug targeting and delivery. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 4099-4108.	3.0	37
46	Capillary electrophoresis method for determination of D-serine and its application for monitoring of serine racemase activity. <i>Electrophoresis</i> , 2006, 27, 2558-2566.	2.4	36
47	Ion specific effects of sodium and potassium on the catalytic activity of HIV-1 protease. <i>Physical Chemistry Chemical Physics</i> , 2009, 11, 7599.	2.8	36
48	Reduced-bond tight-binding inhibitors of HIV-1 protease Fine tuning of the enzyme subsite specificity. <i>FEBS Letters</i> , 1992, 298, 9-13.	2.8	35
49	Structural insight into the evolutionary and pharmacologic homology of glutamate carboxypeptidases II and III. <i>FEBS Journal</i> , 2009, 276, 4448-4462.	4.7	33
50	Hydroxamic Acids As a Novel Family of Serine Racemase Inhibitors: Mechanistic Analysis Reveals Different Modes of Interaction with the Pyridoxal-5-phosphate Cofactor. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 6032-6041.	6.4	33
51	Specificity studies on retroviral proteinase from myeloblastosis-associated virus. <i>Biochemistry</i> , 1991, 30, 3437-3443.	2.5	32
52	iBodies: Modular Synthetic Antibody Mimetics Based on Hydrophilic Polymers Decorated with Functional Moieties. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 2356-2360.	13.8	31
53	The yeast proteases Ddi1 and Wss1 are both involved in the DNA replication stress response. <i>DNA Repair</i> , 2019, 80, 45-51.	2.8	31
54	Stimulated Emission Depletion Nanoscopy Reveals Time-Course of Human Immunodeficiency Virus Proteolytic Maturation. <i>ACS Nano</i> , 2016, 10, 8215-8222.	14.6	30

#	ARTICLE	IF	CITATIONS
55	Amino acids at the N- and C-termini of human glutamate carboxypeptidase II are required for enzymatic activity and proper folding. <i>FEBS Journal</i> , 2004, 271, 2782-2790.	0.2	29
56	Induced Maturation of Human Immunodeficiency Virus. <i>Journal of Virology</i> , 2014, 88, 13722-13731.	3.4	29
57	Design of Highly Potent Urea-Based, Exosite-Binding Inhibitors Selective for Glutamate Carboxypeptidase II. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4357-4363.	6.4	29
58	Proteinases of betaretroviruses bind single-stranded nucleic acids through a novel interaction module, the G-patch. <i>FEBS Letters</i> , 2004, 576, 271-276.	2.8	28
59	Kinetics of the dimerization of retroviral proteases: The "fireman's grip" and dimerization. <i>Protein Science</i> , 2009, 12, 2173-2182.	7.6	27
60	Configurations of Diastereomeric Hydroxyethylene Isosteres Strongly Affect Biological Activities of a Series of Specific Inhibitors of Human-Immunodeficiency-Virus Proteinase. <i>FEBS Journal</i> , 1997, 250, 559-566.	0.2	25
61	Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis. <i>FEBS Journal</i> , 2007, 274, 4731-4741.	4.7	25
62	Triggering HIV polyprotein processing by light using rapid photodegradation of a tight-binding protease inhibitor. <i>Nature Communications</i> , 2015, 6, 6461.	12.8	25
63	Inhibitor-GCPII Interaction: Selective and Robust System for Targeting Cancer Cells with Structurally Diverse Nanoparticles. <i>Molecular Pharmaceutics</i> , 2018, 15, 2932-2945.	4.6	25
64	Exploiting the unique features of Zika and Dengue proteases for inhibitor design. <i>Biochimie</i> , 2019, 166, 132-141.	2.6	25
65	Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir. <i>Protein Science</i> , 2008, 17, 1555-1564.	7.6	24
66	HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat. <i>Retrovirology</i> , 2011, 8, 70.	2.0	23
67	Determining and Overcoming Resistance to HIV Protease Inhibitors. <i>Current Drug Targets Infectious Disorders</i> , 2004, 4, 137-152.	2.1	23
68	A Phenylnorstatine Inhibitor Binding to HIV-1 Protease: Å Geometry, Protonation, and Subsite Å Pocket Interactions Analyzed at Atomic Resolution. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 2030-2036.	6.4	22
69	Structural and biochemical characterization of the foylâ€polyâ€³â€glutamate hydrolyzing activity of human glutamate carboxypeptidase II. <i>FEBS Journal</i> , 2014, 281, 3228-3242.	4.7	22
70	High-level expression of enzymatically active bovine leukemia virus proteinase in <i>E. coli</i> . <i>FEBS Letters</i> , 1991, 287, 129-132.	2.8	21
71	Comparison of human glutamate carboxypeptidases II and III reveals their divergent substrate specificities. <i>FEBS Journal</i> , 2016, 283, 2528-2545.	4.7	21
72	Inhibitor-Decorated Polymer Conjugates Targeting Fibroblast Activation Protein. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 8385-8393.	6.4	21

#	ARTICLE	IF	CITATIONS
73	Capturing a dynamically interacting inhibitor by paramagnetic NMR spectroscopy. <i>Physical Chemistry Chemical Physics</i> , 2019, 21, 5661-5673.	2.8	21
74	Unraveling the anti-influenza effect of flavonoids: Experimental validation of luteolin and its congeners as potent influenza endonuclease inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2020, 208, 112754.	5.5	21
75	Novel Substrate-Based Inhibitors of Human Glutamate Carboxypeptidase II with Enhanced Lipophilicity. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 7535-7546.	6.4	20
76	Prostate-specific membrane antigen and its truncated form PSM ² . <i>Prostate</i> , 2009, 69, 471-479.	2.3	19
77	Potency Comparison of Peptidomimetic Inhibitors against HIV-1 and HIV-2 Proteinases: Design of Equipotent Lead Compounds. <i>Archives of Biochemistry and Biophysics</i> , 1997, 341, 62-69.	3.0	18
78	A Picomolar Inhibitor of Resistant Strains of Human Immunodeficiency Virus Protease Identified by a Combinatorial Approach. <i>Archives of Biochemistry and Biophysics</i> , 2000, 382, 22-30.	3.0	18
79	Hydroxyethylamine Isostere of an HIV-1 Protease Inhibitor Prefers Its Amine to the Hydroxy Group in Binding to Catalytic Aspartates. A Synchrotron Study of HIV-1 Protease in Complex with a Peptidomimetic Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 1432-1438.	6.4	18
80	Inhibitor binding at the protein interface in crystals of a HIV-1 protease complex. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2004, 60, 1943-1948.	2.5	18
81	Label-free determination of prostate specific membrane antigen in human whole blood at nanomolar levels by magnetically assisted surface enhanced Raman spectroscopy. <i>Analytica Chimica Acta</i> , 2018, 997, 44-51.	5.4	18
82	HIV-1 Protease Mutations and Inhibitor Modifications Monitored on a Series of Complexes. Structural Basis for the Effect of the A71V Mutation on the Active Site. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 5777-5784.	6.4	17
83	Kinetic, Thermodynamic, and Structural Analysis of Drug Resistance Mutations in Neuraminidase from the 2009 Pandemic Influenza Virus. <i>Viruses</i> , 2018, 10, 339.	3.3	17
84	A Modular Approach to HIV-1 Proteinase Inhibitor Design. <i>Biochemical and Biophysical Research Communications</i> , 1996, 222, 38-43.	2.1	16
85	Homology modeling and SAR analysis of <i>Schistosoma japonicum</i> cathepsin D (SjCD) with statin inhibitors identify a unique active site steric barrier with potential for the design of specific inhibitors. <i>Biological Chemistry</i> , 2005, 386, 339-349.	2.5	16
86	Mouse glutamate carboxypeptidase II (GCP ^{II}) has a similar enzyme activity and inhibition profile but a different tissue distribution to human GCP ^{II} . <i>FEBS Open Bio</i> , 2017, 7, 1362-1378.	2.3	15
87	Investigation of flexibility of neuraminidase 150-loop using tamiflu derivatives in influenza A viruses H1N1 and H5N1. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 2935-2947.	3.0	15
88	Detection and quantitation of glutamate carboxypeptidase II in human blood. <i>Prostate</i> , 2014, 74, 768-780.	2.3	14
89	Structural and Biochemical Characterization of a Novel Aminopeptidase from Human Intestine. <i>Journal of Biological Chemistry</i> , 2015, 290, 11321-11336.	3.4	14
90	Re-emerging Aspartic Protease Targets: Examining <i>Cryptococcus neoformans</i> Major Aspartyl Peptidase 1 as a Target for Antifungal Drug Discovery. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 6706-6719.	6.4	14

#	ARTICLE	IF	CITATIONS
91	Subsite specificity of the proteinase from myeloblastosis associated virus. <i>FEBS Letters</i> , 1991, 282, 73-76.	2.8	13
92	Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants. <i>Journal of Clinical Virology</i> , 2006, 36, 50-59.	3.1	12
93	Medicinal Application of Carboranes. , 2011, , 41-70.		12
94	Inhibition of the precursor and mature forms of HIV-1 protease as a tool for drug evaluation. <i>Scientific Reports</i> , 2018, 8, 10438.	3.3	12
95	The Murine Endogenous Retrovirus MIA14 Encodes an Active Aspartic Proteinase That Is Functionally Similar to Proteinases from D-Type Retroviruses. <i>Archives of Biochemistry and Biophysics</i> , 2002, 398, 261-268.	3.0	11
96	An Ethylenamine Inhibitor Binds Tightly to Both Wild Type and Mutant HIV-1 Proteases. Structure and Energy Study. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 1636-1644.	6.4	11
97	DNA-linked Inhibitor Antibody Assay (DIANA) for sensitive and selective enzyme detection and inhibitor screening. <i>Nucleic Acids Research</i> , 2017, 45, e10-e10.	14.5	11
98	Ion specific effects of alkali cations on the catalytic activity of HIV-1 protease. <i>Faraday Discussions</i> , 2013, 160, 359-370.	3.2	10
99	Inhibitor-Polymer Conjugates as a Versatile Tool for Detection and Visualization of Cancer-Associated Carbonic Anhydrase Isoforms. <i>ACS Omega</i> , 2019, 4, 6746-6756.	3.5	10
100	GS-8374, a Prototype Phosphonate-Containing Inhibitor of HIV-1 Protease, Effectively Inhibits Protease Mutants with Amino Acid Insertions. <i>Journal of Virology</i> , 2014, 88, 3586-3590.	3.4	9
101	Kinetic, thermodynamic and structural analysis of tamiphosphor binding to neuraminidase of H1N1 (2009) pandemic influenza. <i>European Journal of Medicinal Chemistry</i> , 2016, 121, 100-109.	5.5	9
102	Identification of Protein Targets of Bioactive Small Molecules Using Randomly Photomodified Probes. <i>ACS Chemical Biology</i> , 2018, 13, 3333-3342.	3.4	9
103	Predicting Effects of Site-Directed Mutagenesis on Enzyme Kinetics by QM/MM and QM Calculations: A Case of Glutamate Carboxypeptidase II. <i>Journal of Physical Chemistry B</i> , 2022, 126, 132-143.	2.6	9
104	A distinct binding mode of a hydroxyethylamine isostere inhibitor of HIV-1 protease. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2001, 57, 472-476.	2.5	8
105	Role of hydroxyl group and R/S configuration of isostere in binding properties of HIV-1 protease inhibitors. <i>FEBS Journal</i> , 2004, 271, 4451-4461.	0.2	8
106	Derivatization chemistry of the double-decker dicobalt sandwich ion targeted to design biologically active substances. <i>Pure and Applied Chemistry</i> , 2012, 84, 2243-2262.	1.9	8
107	Structural and Thermodynamic Analysis of the Resistance Development to Pimodivir (VX-787), the Clinical Inhibitor of Cap Binding to PB2 Subunit of Influenza A Polymerase. <i>Molecules</i> , 2021, 26, 1007.	3.8	8
108	GCP II and its close homolog GCP III from a neuropeptidase to a cancer marker and beyond. <i>Frontiers in Bioscience - Landmark</i> , 2019, 24, 648-687.	3.0	8

#	ARTICLE	IF	CITATIONS
109	Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies. <i>Antiviral Research</i> , 2008, 78, 275-277.	4.1	7
110	Synthesis and In Vitro Evaluation of C-7 and C-8 Luteolin Derivatives as Influenza Endonuclease Inhibitors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7735.	4.1	7
111	Characterisation of Mutated Proteinases Derived from HIV-Positive Patients: Enzyme Activity, Vitality and Inhibition. <i>Collection of Czechoslovak Chemical Communications</i> , 2004, 69, 703-714.	1.0	6
112	Response of HIV positive patients to the long-term salvage therapy by lopinavir/ritonavir. <i>Journal of Clinical Virology</i> , 2005, 33, 319-323.	3.1	6
113	Inhibitor and Substrate Binding Induced Stability of HIV-1 Protease against Sequential Dissociation and Unfolding Revealed by High Pressure Spectroscopy and Kinetics. <i>PLoS ONE</i> , 2015, 10, e0119099.	2.5	6
114	A Modular Synthesis of <i>N</i> -Benzotriazole Ureas Using Alkylation of 5-Nitrobenzotriazole. <i>ChemistrySelect</i> , 2016, 1, 101-107.	1.5	6
115	Tris-(Nitrilotriacetic Acid)-Decorated Polymer Conjugates as Tools for Immobilization and Visualization of His-Tagged Proteins. <i>Catalysts</i> , 2019, 9, 1011.	3.5	6
116	Structure-activity relationship and biochemical evaluation of novel fibroblast activation protein and prolyl endopeptidase inhibitors with β -ketoamide warheads. <i>European Journal of Medicinal Chemistry</i> , 2021, 224, 113717.	5.5	6
117	DNA-linked inhibitor antibody assay (DIANA) as a new method for screening influenza neuraminidase inhibitors. <i>Biochemical Journal</i> , 2018, 475, 3847-3860.	3.7	5
118	The calcium-binding site of human glutamate carboxypeptidase II is critical for dimerization, thermal stability, and enzymatic activity. <i>Protein Science</i> , 2018, 27, 1575-1584.	7.6	5
119	structural characterization of the interaction between the C-terminal domain of the influenza polymerase PA subunit and an optimized small peptide inhibitor. <i>Antiviral Research</i> , 2021, 185, 104971.	4.1	5
120	Glutamate carboxypeptidase II does not process amyloid β peptide. <i>FASEB Journal</i> , 2013, 27, 2626-2632.	0.5	4
121	Synthesis and evaluation of 2-pyridinylpyrimidines as inhibitors of HIV-1 structural protein assembly. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 3487-3490.	2.2	4
122	Anomalous adsorptive properties of HIV protease: Indication of two-dimensional crystallization?. <i>Colloids and Surfaces B: Biointerfaces</i> , 2008, 64, 145-149.	5.0	3
123	A novel PSMA/GCPII-deficient mouse model shows enlarged seminal vesicles upon aging. <i>Prostate</i> , 2019, 79, 126-139.	2.3	3
124	The role of the biotin linker in polymer antibody mimetics, iBodies, in biochemical assays. <i>Polymer Chemistry</i> , 2021, 12, 6009-6021.	3.9	3
125	Random mutagenesis of human serine racemase reveals residues important for the enzymatic activity. <i>Collection of Czechoslovak Chemical Communications</i> , 2010, 75, 59-79.	1.0	3
126	Unorthodox Inhibitors of HIV Protease: Looking Beyond Active-site-directed Peptidomimetics. <i>Current Pharmaceutical Design</i> , 2014, 20, 3389-3397.	1.9	3

#	ARTICLE	IF	CITATIONS
127	Czech bibliometric system fosters mediocre research. <i>Nature</i> , 2009, 460, 1079-1079.	27.8	2
128	Identification of Novel Carbonic Anhydrase IX Inhibitors Using High-Throughput Screening of Pooled Compound Libraries by DNA-Linked Inhibitor Antibody Assay (DIANA). <i>SLAS Discovery</i> , 2020, 25, 1026-1037.	2.7	2
129	Chapter 3. Glutamate Carboxypeptidase II as a Therapeutic Target. <i>RSC Drug Discovery Series</i> , 2011, , 62-95.	0.3	2
130	The development of a high-affinity conformation-sensitive antibody mimetic using a biocompatible copolymer carrier (iBody). <i>Journal of Biological Chemistry</i> , 2021, 297, 101342.	3.4	2
131	Proteolytic Processing of Particle-Associated Retroviral Polyproteins by Homologous and Heterologous Viral Proteinases. <i>FEBS Journal</i> , 1995, 228, 191-198.	0.2	1
132	On the role of the configuration of the reaction-intermediate isostere in HIV-1 protease-inhibitor binding: X-ray structure at 2.0 Å resolution. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2006, 62, 489-497.	2.5	1
133	Analysis of substrate specificity of HIV protease species. , 2002, , 474-475.		1
134	Synthesis of library of HIV proteases inhibitors. , 1999, , .		1
135	Simian Immunodeficiency Virus Retropepsin. , 2013, , 204-207.		0
136	Miscellaneous Viral Retropepsins. , 2013, , 237-240.		0
137	Spumapepsins. , 2013, , 245-248.		0
138	iBodies: Modular Synthetic Antibody Mimetics Based on Hydrophilic Polymers Decorated with Functional Moieties. <i>Angewandte Chemie</i> , 2016, 128, 2402-2406.	2.0	0
139	Enzymes HIV Protease. , 2021, , 264-269.		0
140	Spumapepsins. , 2004, , 188-190.		0
141	Miscellaneous viral retropepsins. , 2004, , 185-187.		0
142	Simian immunodeficiency virus retropepsin. , 2004, , 158-160.		0
143	Short, tight-binding inhibitors of HIV-1 protease with dipeptide isosteres at the P1-P1' site. , 1993, , 803-804.		0